Enteric Disease Testing Market - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
Enteric Disease Testing Market |
Salmonellosis, shigellosis, giardiasis,
campylobacteriosis, cryptosporidiosis, and cholera are examples of Enteric Diseases, which are intestinal
infections brought on by a range of bacteria, viruses, and parasites when they
enter the body through the mouth or digestive tracts.
According To Coherent Market
Insights, The Global Enteric Disease Testing Market Is Estimated To Account For
US$ 4,432.7 Mn In Terms Of Value By The End Of 2027.
According to a number of
epidemiological sources, including the WHO, CDC, and NCBI, developing nations
are responsible for around 85% of the global incidence of enteric diseases.
However, because of a lack of awareness, inadequate laboratory conditions, and
deplorable economic situations in these areas, a sizable population who suffers
from numerous intestinal diseases lacks access to basic diagnostic facilities.
Rapid dipstick tests that are
affordable and easy to use are anticipated to develop significantly throughout
the projection period since they do not require a laboratory environment for
diagnosis and may be completed by patients. Enteric
Disease Testing Market demand for more modern technology-based
laboratory tests, such EIA and PCR testing, may expand in nations with more
developed economies, like India, China, Mexico, and Brazil.
The global burden of enteric
illness infection can have a significant impact on health care costs and
potentially result in fatalities. One of the enteric infections, typhoid
salmonellosis, alone causes 16 million new cases and almost 600,000 fatalities
each year. The only method to manage this load is by early diagnosis of
intestinal illnesses. Assays that may quickly diagnose sickness, like enzyme
immunoassay (EIA), PCR-based testing, and dipstick-based tests, are replacing
labor- and time-intensive traditional culture procedures. One of the key
reasons propelling the Enteric Disease
Testing Market is the rise in demand for quick diagnostic tests.
Molecular diagnostic methods like
multiplexed assays are more recent in the field of medicine than singleplex
assays. Equipment for multiplexed assays is therefore rather pricey. Compared
to singleplex assay tests, multiplexed assay tests are less expensive per test,
although initial instrument installation costs are greater.
Larger hospitals, research
centres, and other healthcare providers can readily afford multiplex diagnostic
devices when you include in the original investment and ongoing maintenance
costs. On the other hand, it can be challenging for smaller healthcare
organisations and institutes to purchase multiplexed assay equipment. This
limits the use of molecular diagnostic tools for Enteric Disease Testing Market.
Additionally, the high cost of
this technology restricts market expansion, particularly in developing
countries. Because of this, it is anticipated that the technology's high price
will be a major barrier until local companies introduce comparable technologies
at a lower price.
Major Companies Involved are- Alere, Inc., Becton Dickinson &
Company, Biomerica, Inc., bioMerieux, Bio-Rad, Cepheid, Coris BioConcept,
DiaSorin, Meridian Bioscience, Inc., Quest Diagnostics, and Trinity Biotech
Comments
Post a Comment